These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 29620995)

  • 1. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
    André T; Vernerey D; Mineur L; Bennouna J; Desrame J; Faroux R; Fratte S; Hug de Larauze M; Paget-Bailly S; Chibaudel B; Bez J; Dauba J; Louvet C; Lepere C; Dupuis O; Becouarn Y; Mabro M; Egreteau J; Bouche O; Deplanque G; Ychou M; Galais MP; Ghiringhelli F; Dourthe LM; Bachet JB; Khalil A; Bonnetain F; de Gramont A; Taieb J;
    J Clin Oncol; 2018 May; 36(15):1469-1477. PubMed ID: 29620995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
    Sobrero A; Lonardi S; Rosati G; Di Bartolomeo M; Ronzoni M; Pella N; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Zagonel V; Maiello E; Barni S; Rulli E; Labianca R;
    J Clin Oncol; 2018 May; 36(15):1478-1485. PubMed ID: 29620994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.
    Yoshino T; Yamanaka T; Oki E; Kotaka M; Manaka D; Eto T; Hasegawa J; Takagane A; Nakamura M; Kato T; Munemoto Y; Takeuchi S; Bando H; Taniguchi H; Gamoh M; Shiozawa M; Mizushima T; Saji S; Maehara Y; Ohtsu A; Mori M
    JAMA Oncol; 2019 Nov; 5(11):1574-1581. PubMed ID: 31513248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial.
    Yamazaki K; Yamanaka T; Shiozawa M; Manaka D; Kotaka M; Gamoh M; Shiomi A; Makiyama A; Munemoto Y; Rikiyama T; Fukunaga M; Ueki T; Shitara K; Shinkai H; Tanida N; Oki E; Sunami E; Ohtsu A; Maehara Y; Yoshino T
    Ann Oncol; 2021 Jan; 32(1):77-84. PubMed ID: 33121997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Japanese multicenter phase II study of adjuvant chemotherapy with mFOLFOX6/CAPOX for stage III colon cancer treatment after D2/D3 lymphadenectomy.
    Yoshimatsu K; Ishibashi K; Koda K; Yokomizo H; Oda N; Oshiro M; Kato H; Oya M; Nakajima H; Ooki S; Maekawa H; Matsunami T; Tsubaki M; Yamada T; Kobayashi M; Tanakaya K; Yokoyama M; Ishida H
    Surg Today; 2019 Jun; 49(6):498-506. PubMed ID: 30953164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
    André T; Meyerhardt J; Iveson T; Sobrero A; Yoshino T; Souglakos I; Grothey A; Niedzwiecki D; Saunders M; Labianca R; Yamanaka T; Boukovinas I; Vernerey D; Meyers J; Harkin A; Torri V; Oki E; Georgoulias V; Taieb J; Shields A; Shi Q
    Lancet Oncol; 2020 Dec; 21(12):1620-1629. PubMed ID: 33271092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin (3 months
    Kim ST; Kim SY; Lee J; Yun SH; Kim HC; Lee WY; Kim TW; Hong YS; Lim SB; Baek JY; Oh JH; Ahn JB; Shin SJ; Han SW; Kim SG; Kang SY; Sym SJ; Zang DY; Kim YH; Choi IS; Kang JH; Kim MJ; Park YS
    J Clin Oncol; 2022 Nov; 40(33):3868-3877. PubMed ID: 35772045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
    Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.
    Souglakos J; Boukovinas I; Kakolyris S; Xynogalos S; Ziras N; Athanasiadis A; Androulakis N; Christopoulou A; Vaslamatzis M; Ardavanis A; Emmanouilides C; Bompolaki I; Kourousis C; Makrantonakis P; Christofyllakis C; Athanasiadis E; Kentepozidis N; Karampeazis A; Katopodi U; Anagnosopoulos A; Papadopoulos G; Prinarakis E; Kalisperi A; Mavroudis D; Georgoulias V
    Ann Oncol; 2019 Aug; 30(8):1304-1310. PubMed ID: 31228203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial.
    Yoshino T; Oki E; Misumi T; Kotaka M; Manaka D; Eto T; Hasegawa J; Takagane A; Nakamura M; Kato T; Munemoto Y; Nakamura F; Bando H; Taniguchi H; Sakamoto Y; Shiozawa M; Nishi M; Horiuchi T; Yamagishi H; Sakamoto J; Mizushima T; Ohtsu A; Mori M
    J Clin Oncol; 2022 Oct; 40(29):3419-3429. PubMed ID: 35512259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial.
    Bennouna J; André T; Campion L; Hiret S; Miglianico L; Mineur L; Touchefeu Y; Artru P; Asmis T; Bouché O; Borde F; Kavan P; Lam YH; Rajpar LS; Emile JF; Jouffroy C; Gill S; Taïeb J
    Clin Colorectal Cancer; 2019 Mar; 18(1):e69-e73. PubMed ID: 30415988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.
    Pagès F; André T; Taieb J; Vernerey D; Henriques J; Borg C; Marliot F; Ben Jannet R; Louvet C; Mineur L; Bennouna J; Desrame J; Faroux R; Kirilovsky A; Duval A; Laurent-Puig P; Svrcek M; Hermitte F; Catteau A; Galon J; Emile JF
    Ann Oncol; 2020 Jul; 31(7):921-929. PubMed ID: 32294529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
    Grothey A; Sobrero AF; Shields AF; Yoshino T; Paul J; Taieb J; Souglakos J; Shi Q; Kerr R; Labianca R; Meyerhardt JA; Vernerey D; Yamanaka T; Boukovinas I; Meyers JP; Renfro LA; Niedzwiecki D; Watanabe T; Torri V; Saunders M; Sargent DJ; Andre T; Iveson T
    N Engl J Med; 2018 Mar; 378(13):1177-1188. PubMed ID: 29590544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
    Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
    JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.
    Gallois C; Shi Q; Pederson LD; André T; Iveson TJ; Sobrero AF; Alberts S; de Gramont A; Meyerhardt JA; George T; Schmoll HE; Souglakos I; Harkin A; Labianca R; Sinicrope FA; Oki E; Shields AF; Boukovinas I; Kerr R; Lonardi S; Yothers G; Yoshino T; Goldberg RM; Taieb J; Papamichael D
    J Clin Oncol; 2024 Jul; 42(19):2295-2305. PubMed ID: 38547438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
    Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
    J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
    Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis.
    Boyne DJ; Cuthbert CA; O'Sullivan DE; Sajobi TT; Hilsden RJ; Friedenreich CM; Cheung WY; Brenner DR
    JAMA Netw Open; 2019 May; 2(5):e194154. PubMed ID: 31099875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.